Company news
Trivarx Limited (ASX:TRI) news
Trivarx Limited news releases on 6ix. Latest, Sep 22, 2026: Stabl-Im Clinical Development Update
Press releases & updates
Stabl-Im Clinical Development Update
September 22, 2026
June 2026 Quarterly Activities Report and Appendix 4C
July 28, 2026
Stabl-Im clinical trial supply milestone achieved
July 15, 2026
CRO Engaged to Advance Stabl-Im Phase 1 Trial
May 21, 2026
March 2026 Quarterly Activities Report and Appendix 4C
April 29, 2026
Dr Danielle Meyrick appointed as CEO
April 28, 2026
Appendix 4D & Half-Year Financial Report to 31 December 2025
February 24, 2026
December 2025 Quarterly Activities Report and Appendix 4C
January 29, 2026
Positive results from US-veteran mental health trial
December 17, 2025
TRI Exercises Option to Advance Acquisition of Stabl-Im
November 4, 2025
September 2025 Quarterly Activities Report and Appendix 4C
October 30, 2025
US-veteran mental health trial patient recruitment complete
October 21, 2025
Acquisition of Stabl-Im technology and Private Placement
October 15, 2025
Reinstatement to Official Quotation
October 15, 2025
Extension of Trading Suspension
October 12, 2025
Suspension from Quotation
October 8, 2025
Inadvertent Lift of Trading Halt
October 8, 2025
Pause in trade
October 7, 2025
Positive interim results from US-veteran focused trial
October 7, 2025
Trading Halt
October 6, 2025
Appendix 4E - Preliminary Final Report
August 28, 2025
June 2025 Quarterly Activities Report and Appendix 4C
July 30, 2025
First patient recruited in innovative mental health trial
June 18, 2025
March 2025 Quarterly Activities Report and Appendix 4C
April 30, 2025
IRB approval for trial with US Dept of Veterans Affairs
April 27, 2025
TrivarX Receives Firm Commitments to Raise $2.25 million
March 16, 2025
Trial with US Department of Veterans Affairs
March 12, 2025
Appendix 4D & Half-Year Financial Report to 31 December 2024
February 28, 2025
December 2024 Quarterly Activities Report and Appendix 4C
January 30, 2025
TrivarX Receives $1.03m R&D Tax Incentive
December 5, 2024
New AI Tool Expands Patient Reach and Market Opportunities
November 6, 2024
September 2024 Quarterly Activities Report and Appendix 4C
October 30, 2024
June 2024 Quarterly Activities Report and Appendix 4C
July 31, 2024
Positive Results from Phase 2 SAMDE Study
July 29, 2024
TrivarX Receives Firm Commitments to Raise $2.5 million
May 1, 2024
March 2024 Quarterly Activities Report and Appendix 4C
April 29, 2024
Appendix 4D & Half-Year Financial Report to 31 December 2023
February 28, 2024
Response to ASX Price Query
February 22, 2024
TrivarX Receives $888k R&D Tax Incentive
February 7, 2024
TRI-001 Algorithm and Phase 2 Trial Update
February 4, 2024
December 2023 Quarterly Activities Report and Appendix 4C
January 31, 2024
Phase 2 SAMDE Study Update
November 19, 2023
Board and Management Transition
October 5, 2023
Letter to Shareholders & Notice of GM & Proxy Form
September 6, 2023
Phase 2 Trial Commences for SAMDE Study
September 3, 2023
Proposed issue of securities - MEB
August 7, 2023
Medibio Receives Firm Commitments to Raise $2.25m
August 7, 2023
June 2023 Quarterly Activities Report and Appendix 4C
July 30, 2023
Phase 1 Trial Completed for SAMDE Study
July 23, 2023
Medibio Completes Share Purchase Plan
May 29, 2023